Autoantibody status in systemic sclerosis patients defines both cancer risk and survival with ANA negativity in cases with concomitant cancer having a worse survival

Por Abdulla Watad, Dennis McGonagle, Nicola L. Bragazzi, Shmuel Tiosano, Doron Comaneshter, Yehuda Shoenfeld, Arnon D. Cohen, Howard Amital
Publicado em 2019-06-01